Question 1

Who are the top researchers at Vivus (United States)?

Accepted Answer

Ranked on the quality score, Craig A. Peterson and Susamma Varghese lead among researchers whose main affiliation is Vivus (United States).

Question 2

What are the most cited papers from Vivus (United States)?

Accepted Answer

The most cited paper from Vivus (United States) is "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial" (Kishore M. Gadde, David Blair Allison, Donna H. Ryan et al., 2011), with 1,062 citations. Next come "Controlled‐Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)" (725) and "Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study" (715).

Question 3

Which research topics does Vivus (United States) publish most on?

Accepted Answer

By volume in 2022-now: Consumer Behavior in Brand Consumption and Identification, Pharmacology and Obesity Treatment, Bariatric Surgery and Outcomes and Diabetes Treatment and Management.

Question 4

Which keywords describe research at Vivus (United States)?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Weight Loss, Clinical Trials, Obesity, Anti-Obesity Drugs, Pharmacotherapy, Cardiovascular Disease, Menopause and Type 2 Diabetes.

Question 5

Which fields of science does Vivus (United States) work in?

Accepted Answer

In all years, 51% of research at Vivus (United States) is in Health Sciences, 25% in Social Sciences. Its largest fields are Medicine (49%), Engineering (9%), Social Sciences (8%). It does 1.8× the world's share of Health Sciences.

Question 6

Is Vivus (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 62% lower than in 2018-2021.